Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLNCF) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Silence Therapeutics (SLNCF) over the last 4 years, with Q3 2025 value amounting to $141.7 million.

  • Silence Therapeutics' Shares Outstanding (Weighted Average) fell 2276.09% to $141.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year decrease of 2276.09%. This contributed to the annual value of $138.8 million for FY2024, which is 46.36% up from last year.
  • According to the latest figures from Q3 2025, Silence Therapeutics' Shares Outstanding (Weighted Average) is $141.7 million, which was down 2276.09% from $141.7 million recorded in Q2 2025.
  • Silence Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $183.5 million during Q3 2024, with a 5-year trough of $113.3 million in Q4 2022.
  • Moreover, its 4-year median value for Shares Outstanding (Weighted Average) was $141.7 million (2025), whereas its average is $149.2 million.
  • Per our database at Business Quant, Silence Therapeutics' Shares Outstanding (Weighted Average) soared by 2191.37% in 2023 and then plummeted by 2276.09% in 2025.
  • Quarter analysis of 4 years shows Silence Therapeutics' Shares Outstanding (Weighted Average) stood at $113.3 million in 2022, then grew by 21.91% to $138.1 million in 2023, then grew by 0.46% to $138.8 million in 2024, then grew by 2.13% to $141.7 million in 2025.
  • Its last three reported values are $141.7 million in Q3 2025, $141.7 million for Q2 2025, and $141.7 million during Q1 2025.